Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3001804 | 0.83 | KMT2A (0.66) | TDP1ALDH1A1KMT2ATP53GAA | |
| SCHEMBL2992964 | 0.81 | ALDH1A1 (1.00) | ALDH1A1TP53CYP1A2CYP2C19GAA | |
| SCHEMBL2996626 | 0.80 | ALDH1A1 (0.61) | TDP1ALDH1A1KMT2ATP53CA1 | |
| SCHEMBL2998860 | 0.80 | ALDH1A1 (0.61) | TDP1ALDH1A1KMT2ATP53CYP1A2 | |
| SCHEMBL3001940 | 0.80 | GAA (0.65) | TDP1ALDH1A1KMT2ATP53GAA | |
| SCHEMBL7401272 | 0.79 | HDAC3 (0.64) | TDP1ALDH1A1TP53CYP1A2CYP2C9 | |
| SCHEMBL3001845 | 0.79 | GAA (0.67) | TDP1ALDH1A1KMT2ATP53GAA | |
| Hydrochloric Acid SCHEMBL2992624 | 0.79 | ALDH1A1 (0.59) | TDP1ALDH1A1KMT2ATP53CYP1A2 | |
| SCHEMBL2997659 | 0.79 | ALDH1A1 (0.70) | TDP1ALDH1A1KMT2ATP53CYP1A2 | |
| SCHEMBL2998188 | 0.79 | ALDH1A1 (0.70) | TDP1ALDH1A1TP53CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | BRIDGE BIORESEARCH RIGHTS (JERSEY) LIMITED (GB) | 2010-07-22 | — | — | US | disclosed |
| EP-2068873-A2 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | Pharma 2100 (DK) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008031440-A2 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | PHARMA 2100 (DK) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | ODC1, OTC, ACACB | TDP1 3641/4885ALDH1A1 302/4885MAPT 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.